Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
EQS-News: ABIVAX: Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in P...
EQS-News: ABIVAX / Key word(s): Quarter Results/Study results Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label
Ähnliche Seiten
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patient...
https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a2b-open-label-extension-trial-of-obefazimod-following-dose-de-escalation-in-patients-with-ulcerative-colitis/2350350